10/12/2018 1 Multimodal Analgesic Alternatives Opioid Minimizing & Opioid Free Strategies Lois Stewart, PhD, CRNA Doctor of Nursing Practice Nurse Anesthesia Program Assistant Professor, Leighton School of Nursing Marian University [email protected]page Standard Disclaimer • I have no financial relationships with any commercial interest related to the content of this activity. • I will likely discuss off-label use during my presentation. page Session Objectives • In this session, multimodal analgesic therapies will be reviewed. This review will focus on multimodal pharmacological interventions, rather than regional anesthetic techniques Briefly review the history of ‘pre-emptive’ analgesia Briefly describe the importance of regional and neuraxial anesthetic techniques in opioid-sparing analgesic regimens Provide an overview of available non-opioid analgesic pharmacological interventions Describe the pharmacologic actions of selected non-opioid analgesic medications
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
• I have no financial relationships with any commercial interest related to the content of this activity.
• I will likely discuss off-label use during my presentation.
page
Session Objectives
• In this session, multimodal analgesic therapies will be reviewed. This review will focus on multimodal pharmacological interventions, rather than regional anesthetic techniques
Briefly review the history of ‘pre-emptive’ analgesia Briefly describe the importance of regional and neuraxial
anesthetic techniques in opioid-sparing analgesic regimens Provide an overview of available non-opioid analgesic
pharmacological interventions Describe the pharmacologic actions of selected non-opioid
analgesic medications
10/12/2018
2
page
Opioid Minimization or Elimination?
page
The Perioperative Goal (Prevention)
http://www.aafp.org/afp/2001/0515/p1979.html
page
Balanced, Multimodal, Pre-emptive (?) Analgesia
• Balanced & Multimodal Analgesics that act on distinct and
varied pain pathway components, to increase efficacy and decrease side effects
• Goal of preemptive analgesia is to prevent the induction of CNS plasticity Initiated prior to procedural trauma Modalities or their effects outlive the
continued generation of noxious stimuli, or at least the most intense period of the same
• Best pre-emptive modalities modify noxious afferent input beforecortical perception
10/12/2018
3
page
Central Neuraxial and Regional Anesthetic Techniques
page
Benefits of Neuraxial or Regional Anesthesia
• Avoidance of large doses of multiple IV medications
• Possible avoidance of general anesthesia and its inherent potential complications throughout the perioperative period
• Less hemodynamic compromise if no general anesthetic
• Less PONV
• Attenuated neuroendocrine stress response
• Decreased thromboembolic complications
• Less time for ambulation and/or discharge, dependent on block utilized
• Less use or no use of opioid agents
page
Considerations w/ Neuraxial or Regional Anesthesia
• Potential longer pre-operative time period
• Limitations due to proper equipment
• Limitations due to proper training or experience
• Complications inherent to each type of blockade
• Risk of systemic local anesthetic toxicity
10/12/2018
4
page
Benefits of Non-opioid Parenteral Analgesics
• No unwanted opioid receptor side effects
• Reduced risk of respiratory depression for patients diagnosed with obesity or OSA
• Reduce risk of immunosuppression and metastatic disease with intraoperative administration of opioids via the opioid receptor effects
• Avoidance of opioid exposure for both naïve and patients with substance abuse history
• No risk of opioid-induced hyperalgesia (OIH)
page
Opioid Induced Hyperalgesia
Felt to be related to acute dose escalation or agent potency
• Increased sensitivity to noxious stimuli
• Known in chronic opioid use for more than 100 years
• Same pathophysiology as neuropathic pain central/peripheral sensitization
• Amide local anesthetic with analgesic, anti-hyperalgesic, and anti-inflammatory properties
• Mediated by sodium channel blockade (VGSCs)
• Inhibition of G-protein coupled receptors and limited NMDA blockade
• Significant reduction in postoperative pain and opioid consumption after abdominal surgery with… Decreased ileus and length of stay
• Dosages: 1.5mg/kg at induction + 1 - 2mg/kg/hr for 24 - 48 hours postop
page
Local Anesthetics
• Lidocaine, procaine and chloroprocaine are the most commonly used for this Given slow bolus or continuous infusion, or both
Component of ERAS protocols
• Modulates neurotransmission via voltage-gated sodium channels
• Has anti-inflammatory properties
• Lidocaine dosing = dose over 5-30” for total dose of 1-5 mg/kg*
Draw up 2% and run it at 0.1ml/kg/hr. (70 kg = 7 ml/hr)
M & M 2015
Colorectal Dis. 2013 Feb;15(2):146-55
Practitioner Consensus: 1.5 mg/kg bolus with 2mg/min gtt (2mg/kg/hr)• Or 1.5 – 2.0 mg/kg bolus q 1 hour
• If good results consider adding oral antiarrhythmic therapy to the CP regimen
• Often used in PACU for acute exacerbation of pain in CP patient
• Can be used intra-operatively in patients with history of CP or with high risk surgery Can be combined with ketamine and/or magnesium gtt in a controlled infusion for additive
effects
page
Ketamine
• FDA approved in 1970 for General Anesthesia
• Unacceptable toxicity including hallucinations and dysphoric reactions at induction doses
• Subanesthetic doses (0.5mg/kg or less) provide analgesia for neuropathic pain
• Subanesthetic doses provide relief from treatment-resistant depression
• Subanesthetic doses lead to improved response to subsequent opioid therapy leading to reduced postoperative pain and opioid requirements.
10/12/2018
9
page
Ketamine
Bell & Nathan, 2017
page
Magnesium
• FDA approved for prevention of seizures (pre-eclampsia) and replacement of magnesium deficiency
• Off label use in ER includes treatment of: acute migraine headache, cardiac arrhythmias including Torsade de pointes, atrial fibrillation, cardiac arrest, bronchospasm, seizures, and alcohol withdrawal
NMDA receptor activation is a key component to nociception and especially to central sensitization• Ketamine has been shown in controlled trials to reverse central
sensitization even after establishment
• Ketamine’s affinity for the NMDA receptor is 20X stronger than for any other binding site; a non-competitive antagonist
• The NMDA receptor cannot activate until magnesium plug is out of the way in the central ion pore of the receptor
• Due to complementary actions on the NMDA receptor, these co-analgesics have synergistic potential (Mg2+ and ketamine)
Mg2+ assists ketamine to bind longer to NMDA receptors
page
Ketamine & Magnesium
• Ketamine should be co-administered with Versed or propofol Will spare the usual needed opioid dose by approximately 50% Should be discontinued in the last 30 minutes prior to surgery end
for outpatients, or those patients without a history of CP
Drip rates: 10-15mg/hr or achieve the same by timed bolus Drip rates: 0.05 – 0.3 mg/kg/hr
Alternative Scheme: Bolus with 25 mg ketamine on induction the hang a drip: 100 mg ketamine plus 3 gm MgSO4 in 250cc NS and run at 50cc/hr. If inpatient CP patient, run drip until 4-5 hours prior to discharge. If CP patient in for elective outpatient surgery, discontinue 30 minutes prior to surgery end.
page
Methadone Intra-operatively
• An opioid that generally does not incur acute tolerance or OIH
• 4 minutes b/w plasma concentration equilibration and pharmacodynamic effects (similar to fentanyl and sufentanil) = rapid onset
• Hepatic metabolism and clearance• Dose dependent elimination half-life
Distributive elimination for small doses Metabolic elimination for large doses (15-60 hours) 20mg, or 0.2 – 0.3 mg/kg as a single induction dose is
recommended
10/12/2018
11
page
Esmolol… not just a unique beta blocker
page
Esmolol
• Selective adrenoreceptor antagonist
• Distribution T1/2 = 2”
• Elimination T1/2 = 9” Organ-independent metabolism by plasma esterases
• Provides hemodynamic stability
• Reduced anesthetic requirements (additive to MAC)
Can also mix 200 cg precedex + 200 mg ketamine in 100 cc NS: run on syringe pump between 15-30 mL/hr
page
Don’t forget the Nitrous… !
10/12/2018
13
page
Examples of OFA – TIVA
• Example # 1: (DLP) OFA
Dexmedetomidine (0.6 mg/kg loading dose, then 0.3 mg/kg/h infusion)
Lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion)
Propofol (50 – 200 mcg/kg/min)
page
Examples of OFA
• Example # 2: (MLK) OFA
Induce GA with propofol and esmolol (20-40 mg) and maintain with volatile agent
Combine in a 100 mL bag of 0.9% NS:
• Magnesium 30 - 60 mg/kg (max 6 g)
• Lidocaine 1 – 1.5 mg/kg
• Infuse over 30– 60 minutes
• Consider second infusion if case is two hours or longer
Ketamine 5 mg/mL in a 10-mL syringe• 5 – 10 mg q 30 minutes
page
The Future: The Utility of Functional MRIs
10/12/2018
14
page
Use your NMDA Receptors to Recall…
• Multiple regions of the brain are linked to, or process, nociceptor activity
• The descending inhibitory system is intricately linked to emotional, cognitive and motivational cortical & subcortical centers
• Limbic, PFC, insular, basal nuclei
• New research these higher centers can influence the activity of the pontomedullary DI centers
• More intense research into the exact mechanisms of the DI system RVM ON cells RVM OFF cells
page
Future Treatments… Coming Soon?
page
REFERENCES
• Bell, J.D. & Nathan, N. (2017). Ketamine for neuroprotection in acute neurologic injury. Anesthesia & Analgesia, 124(4), 1237-1243.
• Brandal, D., Keller, M.S., Lee, C., Grogan, T., Fujimoto, Y., … Cannesson, M. (2017). Impact of enhanced recovery after surgery and opioid-free anesthesia on opioid prescriptions at discharge from the hospital: A historical-prospective study. Anesthesia & Analgesia, 125(5), 1784-1792.
• Do, S. (2013). Magnesium: a versatile drug for anesthesiologists. Korean Journal of Anesthesiology, 65(1), 4–8.
• Dunn, L. & Durieux, M. (2017). Perioperative use of intravenous lidocaine. Anesthes, 126(4):729-737.
• Glass, P.S., Collard, A., Vincent, M.D., Mistraletti, G., …Franco, M.P. (2007). Intraoperative esmolol infusion in the absence of opioids spares postoperative fentanyl in patients undergoing ambulatory laparoscopic cholecystectomy. Anesthesia & Analgesia, 105(5), 1255-1262.
• Gorlin, A., Rosenfeld, D., & Ramakrishna, H. (2016). Intravenous sub-anesthetic ketamine for perioperative analgesia. Journal of Anaesthesiology, Clinical Pharmacology, 32(2), 160–167.
• Herroeder, S., Schönherr, M., De Hert, S., & Hollmann, M. (2011). Magnesium: essentials for anesthesiologists. Anesthes, 114(4):971-993.
• International Anesthesia Research Society, (2014). Esmolol. Retrieved from https://www.openanesthesia.org/esmolol/
• Kandil, E., Melikman, E., & Adinoff, B. (2017). Lidocaine infusion: a promising therapeutic approach for chronic pain. Journal of Anesthesia & Clinical Research, 8(1), 697.
• Kurdi, M., Theerth, K., & Deva, R. (2014). Ketamine: current applications in anesthesia, pain, and critical care. Anesthesia, Essays and Researches, 8(3), 283–290.
• Sammour, T., Zargar-Shoshtari, K., Bhat, A., Kahokehr, A., & Hill, A.G. (2010). A programme of Enhanced Recovery After Surgery (ERAS) is a cost-effective intervention in elective colonic surgery. N Z Med J, 123(1319), 61-70.
• Sleigh, J., Harvey, M., Voss, L. & Denny, B. (2014) Ketamine – more mechanisms of action than just NMDA blockade. Trends in Anesthesia and Critical Care, 4, 76 – 81.
• Surana, A. (2016) Role of magnesium: a step ahead in anaesthesia. J Anesth Crit Care Open Access, 6(1): 00218. • Wanderer, J.P. & Nathan, N. (2016). Anesthetizing patients and their immune systems: Volatile anesthetics at work.